ClinicalTrials.gg
TerminatedNCT02630563Updated May 19, 2016Results posted

Safety, Tolerability and Pharmacokinetics of Oral CellCept (Mycophenolate Mofetil) in Pediatric Liver Transplant Recipients on Concomitant Treatment With Cyclosporine and Corticosteroids

A Phase 2 interventional study of Corticosteroids and Cyclosporine in Pediatric Liver Transplantation, sponsored by Hoffmann-La Roche. Terminated at 2 sites in United States. Open to participants aged 3 Months to 12 Years. Per ClinicalTrials.gov, last updated 2016-05-19.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Why this study was terminated
Due to extremely slow recruitment, infrequent use of combination triple therapy (MMF, cyclosporine, steroids), study was discontinued; Part 2 was not conducted.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
3 Months to 12 Years
Sex
All
01

Study summary

The study is planned to be conducted in 2 parts. The first part (open label, multi-center, non-controlled) of the study will estimate a dose that would provide a mycophenolic acid (MPA) exposure in pediatric participant that is comparable to that achieved in adult liver transplant participants receiving the approved dose of mycophenolate mofetil (MMF, CellCept). The second part (open-label, multi-center, single-arm Phase IV study) of the study will provide the pharmacokinetics, efficacy and safety profile of the proposed dose in the immediate post-transplant period. This study will be conducted at two centers based in the United States of America. Twelve pediatric transplant participants receiving a first liver allograft from a cadaveric or living donor will be enrolled in this study. Stable pediatric liver transplant participants who are at least 6 months post-transplant and who were already receiving stable dose of MMF in combination with cyclosporine will be enrolled into the study. Participants should have received stable MMF dose according to center practice for at least seven days in order to get steady state pharmacokinetics (PK). Participants also should have received stable concomitant doses of cyclosporine (for at least 2 days) and corticosteroids per center practice. Participants will be aged between 9 months and 12 years, with at least 6 participants greater than or equal to (>/=) 9 months and less than (\<) 36 months, of whom at least 2 will be \<24 months.

02

Conditions studied

  • Pediatric Liver Transplantation
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Months to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participant must be between 3 months and 12 years of age
  • Participant is a recipient of a first liver allograft from cadaveric or living donors
  • Participant is a single-organ recipient (liver only)
  • Female participants of must have a negative serum or urine pregnancy test with a sensitivity of at least 50 milli International Units per milliliter (mIU/mL) within one week prior to PK sampling
  • Female participants of childbearing potential must use two reliable forms of simultaneously unless abstinence is the chosen method
  • Effective contraception must be used before beginning of PK sampling
  • Participants must be able to receive oral medication
  • Participants must be at least 6 months post-transplant and had started on MMF in the early post-transplant period (within 2 weeks of transplant)
  • Participants must be receiving stable doses of MMF per center practice for at least 7 days prior to PK sampling
  • In addition, participants must be receiving stable doses of cyclosporine and , according to center practice
  • Participants' parent/guardian are capable of understanding the purposes and risks of the study and must sign an for the study

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing adolescents
  • Participants who had undergone dialysis within two weeks before PK sampling
  • Participants with active systemic infections
  • Participants with (ANC) of less than 1300 per microliter (µL), or counts less than 50 000/µL or at a concentration below a set lower limit (according to center practice, but not less than 8 grams per deciliter) at the time of study entry
  • Participants with active peptic ulcer disease
  • Participants with severe diarrhea (more than 5 watery stools per day) or other gastrointestinal disorders which might interfere with their ability to absorb oral medication
  • History of positive (HIV) test
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Mycophenolate Mofetil+Corticosteroids+Cyclosporine

    Part 1: Participants will receive mycophenolate mofetil. Part 2: Participants will receive mycophenolate mofetil along with cyclosporine and corticosteroids.

    Drug: Corticosteroids · Drug: Cyclosporine · Drug: mycophenolate mofetil

Interventions

  • DrugCorticosteroids

    Corticosteroids will be administered as per center practice. The choice of corticosteroid drug will also be based on center practice.

  • Cyclosporine will be administered as per center practice.

  • Part 1: Mycophenolate mofetil will be administered as per center practice. Part 2: Mycophenolate mofetil will be administered as per dose determined in Part 1.

    Also known as: CellCept

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Curve From 0 to 12 Hours of Mycophenolic Acid Normalized for Dose And for Body Surface Area

    The area under the plasma concentration-time curve from time zero to twelve hours (AUC \[0-12h\]) is area under the plasma concentration-time curve from time zero through 12 hours. AUC (0-12) hours was computed using the linear trapezoidal rule. For the calculations of AUC (0-12h), concentrations below the limit of quantification were assigned a value of zero if they occurred at the beginning of a profile. When such values appeared at the end of a profile they were assigned as missing data. AUC0-12h was normalized to 600 milligram per square meter (mg/m\^2) and 1.5 gram. AUC was reported in microgram hour per milliliter (mcg\*h/mL).

    Time frame: Pre-dose, 0.5, 0.75, 1.0, 1.5, 2.0, 4.0, 8.0, and 12.0 hours post oral dosing for participants greater than (>) 24 months, and at pre-dose, 0.75, 2.0, 4.0 and 12.0 hours post oral dosing for participants less than (<) 24 months

Secondary outcomes

  1. Area Under the Plasma Concentration Time Curve From 0-12 Hours for Mycophenolic Acid and Mycophenolic Acid Glucuronide Phenolic Glucuronide of Mycophenolic Acid

    The area under the plasma concentration-time curve from time zero to twelve hours (AUC \[0-12h\]) is area under the plasma concentration-time curve from time zero through 12 hours. AUC (0-12) hours was computed using the linear trapezoidal rule. For the calculations of AUC (0-12h), concentrations below the limit of quantification were assigned a value of zero if they occurred at the beginning of a profile. When such values appeared at the end of a profile they were assigned as missing data. AUC was reported in microgram hour per milliliter (mcg\*h/mL).

    Time frame: Pre-dose, 0.5, 0.75, 1.0, 1.5, 2.0, 4.0, 8.0, and 12.0 hours post oral dosing for participants greater than (>) 24 months, and at pre-dose, 0.75, 2.0, 4.0 and 12.0 hours post oral dosing for participants less than (<) 24 months

  2. Maximum Plasma Concentration for Mycophenolic Acid and Mycophenolic Acid Glucuronide

    The Plasma Concentration (Cmax) is defined as maximum observed analyte concentration. Cmax was obtained directly from the measured plasma concentration-time curves.

    Time frame: Pre-dose, 0.5, 0.75, 1.0, 1.5, 2.0, 4.0, 8.0, and 12.0 hours post oral dosing for participants > 24 months, and at pre-dose, 0.75, 2.0, 4.0 and 12.0 hours post oral dosing for participants < 24 months

  3. Time to Maximum Plasma Concentration for Mycophenolic Acid and Mycophenolic Acid Glucuronide

    Tmax is the amount of time after dosing to when the maximum concentration of MPA and MPAG was achieved.

    Time frame: Pre-dose, 0.5, 0.75, 1.0, 1.5, 2.0, 4.0, 8.0, and 12.0 hours post oral dosing for participants > 24 months, and at pre-dose, 0.75, 2.0, 4.0 and 12.0 hours post oral dosing for participants < 24 months

  4. Number of Participants With Adverse Events and Serious Adverse Events

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is a significant medical event.

    Time frame: Up to Day 32

  5. Plasma Concentration of Mycophenolic Acid and Its Metabolite Mycophenolic Acid Glucuronide at Each Time Point

    Mycophenolic Acid Glucuronide (MPAG) is an active metabolite of Mycophenolic Acid (MPA).

    Time frame: Pre-dose, 0.5, 0.75, 1.0, 1.5, 2.0, 4.0, 8.0, and 12.0 hours post oral dosing for participants greater than (>) 24 months, and at pre-dose, 0.75, 2.0, 4.0 and 12.0 hours post oral dosing for participants less than (<) 24 months

07

Results

Posted Apr 12, 2016
Limitations and caveats
Part I of the study was terminated early with 9 participants enrolled (8 of which were evaluable for PK), and Part II of the study was not performed due to extremely slow recruitment and the infrequent use of the combination of triple therapy.

Participant flow

The study was conducted between 02 May 2003 and 20 January 2005. This study was conducted at 2 sites in United States (US). Overall, 9 participants entered the study.

Participant flow — Overall Study
MilestoneDrug MMF
Started9
Completed8
Not completed1
Withdrew: Administrative1

Outcome measures

SecondaryArea Under the Plasma Concentration Time Curve From 0-12 Hours for Mycophenolic Acid and Mycophenolic Acid Glucuronide Phenolic Glucuronide of Mycophenolic Acid

The area under the plasma concentration-time curve from time zero to twelve hours (AUC \[0-12h\]) is area under the plasma concentration-time curve from time zero through 12 hours. AUC (0-12) hours was computed using the linear trapezoidal rule. For the calculations of AUC (0-12h), concentrations below the limit of quantification were assigned a value of zero if they occurred at the beginning of a profile. When such values appeared at the end of a profile they were assigned as missing data. AUC was reported in microgram hour per milliliter (mcg\*h/mL).

Time frame:
Pre-dose, 0.5, 0.75, 1.0, 1.5, 2.0, 4.0, 8.0, and 12.0 hours post oral dosing for participants greater than (>) 24 months, and at pre-dose, 0.75, 2.0, 4.0 and 12.0 hours post oral dosing for participants less than (<) 24 months
Reported as:
Mean · mcg*h/mL
Area Under the Plasma Concentration Time Curve From 0-12 Hours for Mycophenolic Acid and Mycophenolic Acid Glucuronide Phenolic Glucuronide of Mycophenolic Acid
mcg*h/mLDrug MMF
MPA Raw29 ± 20.3
MPAG Raw487 ± 185
MPAG (MPA Equivalents)289 ± 109
SecondaryMaximum Plasma Concentration for Mycophenolic Acid and Mycophenolic Acid Glucuronide

The Plasma Concentration (Cmax) is defined as maximum observed analyte concentration. Cmax was obtained directly from the measured plasma concentration-time curves.

Time frame:
Pre-dose, 0.5, 0.75, 1.0, 1.5, 2.0, 4.0, 8.0, and 12.0 hours post oral dosing for participants > 24 months, and at pre-dose, 0.75, 2.0, 4.0 and 12.0 hours post oral dosing for participants < 24 months
Reported as:
Mean · mcg/mL
Maximum Plasma Concentration for Mycophenolic Acid and Mycophenolic Acid Glucuronide
mcg/mLDrug MMF
MPA Raw7.98 ± 3.69
MPAG Raw54.6 ± 26.8
MPAG (MPA Equivalents)32.4 ± 15.9
SecondaryTime to Maximum Plasma Concentration for Mycophenolic Acid and Mycophenolic Acid Glucuronide

Tmax is the amount of time after dosing to when the maximum concentration of MPA and MPAG was achieved.

Time frame:
Pre-dose, 0.5, 0.75, 1.0, 1.5, 2.0, 4.0, 8.0, and 12.0 hours post oral dosing for participants > 24 months, and at pre-dose, 0.75, 2.0, 4.0 and 12.0 hours post oral dosing for participants < 24 months
Reported as:
Median · hour
Time to Maximum Plasma Concentration for Mycophenolic Acid and Mycophenolic Acid Glucuronide
hourDrug MMF
MPA Raw1.35 (0.5 to 2.03)
MPAG Raw1.99 (1.52 to 4.13)
SecondaryNumber of Participants With Adverse Events and Serious Adverse Events

An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is a significant medical event.

Time frame:
Up to Day 32
Reported as:
Number · participants
Number of Participants With Adverse Events and Serious Adverse Events
participantsDrug MMF
Participants with AE1
Participants with SAE0
PrimaryArea Under the Plasma Concentration-Time Curve From 0 to 12 Hours of Mycophenolic Acid Normalized for Dose And for Body Surface Area

The area under the plasma concentration-time curve from time zero to twelve hours (AUC \[0-12h\]) is area under the plasma concentration-time curve from time zero through 12 hours. AUC (0-12) hours was computed using the linear trapezoidal rule. For the calculations of AUC (0-12h), concentrations below the limit of quantification were assigned a value of zero if they occurred at the beginning of a profile. When such values appeared at the end of a profile they were assigned as missing data. AUC0-12h was normalized to 600 milligram per square meter (mg/m\^2) and 1.5 gram. AUC was reported in microgram hour per milliliter (mcg\*h/mL).

Time frame:
Pre-dose, 0.5, 0.75, 1.0, 1.5, 2.0, 4.0, 8.0, and 12.0 hours post oral dosing for participants greater than (>) 24 months, and at pre-dose, 0.75, 2.0, 4.0 and 12.0 hours post oral dosing for participants less than (<) 24 months
Reported as:
Mean · mcg*h/mL
Area Under the Plasma Concentration-Time Curve From 0 to 12 Hours of Mycophenolic Acid Normalized for Dose And for Body Surface Area
mcg*h/mLDrug MMF
Normalized to 600mg/m^265.6 ± 56.2
Normalized to 1.5g363 ± 360
SecondaryPlasma Concentration of Mycophenolic Acid and Its Metabolite Mycophenolic Acid Glucuronide at Each Time Point

Mycophenolic Acid Glucuronide (MPAG) is an active metabolite of Mycophenolic Acid (MPA).

Time frame:
Pre-dose, 0.5, 0.75, 1.0, 1.5, 2.0, 4.0, 8.0, and 12.0 hours post oral dosing for participants greater than (>) 24 months, and at pre-dose, 0.75, 2.0, 4.0 and 12.0 hours post oral dosing for participants less than (<) 24 months
Reported as:
Mean · mcg/mL
Plasma Concentration of Mycophenolic Acid and Its Metabolite Mycophenolic Acid Glucuronide at Each Time Point
mcg/mLDrug MMF
Raw MPA at 0.00.786 ± 0.681
Raw MPA at 0.509.03 ± 4.34
Raw MPA at 0.755.67 ± 3.14
Raw MPA at 1.005.84 ± 3.13
Raw MPA at 1.506.16 ± 5.08
Raw MPA at 2.006.23 ± 4.54
Raw MPA at 4.001.89 ± 1.90
Raw MPA at 8.001.38 ± 1.72
Raw MPA at 12.000.676 ± 0.795
Raw MPAG at 0.0026.2 ± 20.4
Raw MPAG at 0.5026.5 ± 1.13
Raw MPAG at 0.7545.8 ± 28.2
Raw MPAG at 1.0037.2 ± 4.81
Raw MPAG at 1.5043.2 ± 12.9
Raw MPAG at 2.0051.0 ± 27.9
Raw MPAG at 4.0046.3 ± 21.3
Raw MPAG at 8.0019.2 ± 13.4
Raw MPAG at 12.0014.6 ± 7.35

Adverse events

Collected over Up to Day 32. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Drug MMF—0/9 (0%)1/9 (11.1%)
Most frequent other events
Most frequent other events
EventDrug MMF
PyrexiaGeneral disorders1/9

Baseline characteristics

All Patient Population included all participants who were enrolled in the trial

Age, Continuous
Age, Continuous(years)Drug MMF
Mean1.3 ± 1.5
Sex: Female, Male
Sex: Female, Male(Participants)Drug MMF
Female5
Male4
08

Study locations

2 sites
  • San Francisco, California 94143-0116, United States
  • New York, New York 10032-3784, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2003, a primary completion of Jan 2005 and a completion of Jan 2005. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 11 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2015
First posted
Dec 15, 2015
Start
May 2003
Primary completionActual
Jan 2005
CompletionActual
Jan 2005
Results first posted
Apr 12, 2016
Last update
May 19, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02630563
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 15, 2015
Start date
May 2003
Primary completion
Jan 2005
Completion
Jan 2005
Results posted
Apr 12, 2016
Last update
May 19, 2016

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclosporine · Mycophenolic Acid

Start the discussion